RAPASAS Study Page

OPEN FOR RECRUITMENT

TriviumVet is supplying TRIV202 to the Morris Animal Foundation research into subvalvular aortic stenosis (SAS), the most common congenital heart defect in dogs. The purpose of this study is to evaluate whether three-times weekly dosing with oral rapamycin (TRIV202) can reverse the heart muscle changes associated with SAS in dogs. As the current treatment options are limited in this disease, this has the potential to provide further treatment options to improve quantity and quality of life for dogs affected by this disease.